This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.
Stocks · News reference
AbbVie Exec Says Apogee Fits 'Very Nicely' With Its Business Development Approach; Says Existing Portfolio Provides 'Clear Line Of Sight' To Very Strong Growth Well Into Next Decade
- conference call
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AbbVie Exec Says Plans To Start Enrolling Apogee's Zumilokibart This Year, Targets Launch In Early 2030; Says Will Present Late-stage Data For Blood Cancer Drug Etentamig At International Myeloma Society Meeting Later In September
https://event.webcasts.com/starthere.jsp?ei=1773801&tp_key=756e5e03ad&tp_special=8
Billionaire Ken Griffin Just Loaded Up on This Dividend King, and Wall Street Still Sees Upside
Ken Griffin's Citadel hedge fund increased its AbbVie stake by over 500% in Q2 2026, signaling confidence in the pharmaceutical company's defensive qualities and dividend strength. AbbVie, a Dividend King with 50+ consecutive annual dividend increases, offers a 2.6% yield and has successfully navigated patent cliffs with new drugs like Skyrizi and Rinvoq. Wall Street analysts remain bullish with 25 of 31 rating it a buy and an average price target of $277.